Investigating how certain natural inhibitors affect spine health
Official title: The role of endogenous low molecular weight mineralization inhibitors in spine health
Funded at Thomas Jefferson University · NIH-11017795 · Data updated 2026-11-12
This study is looking at how certain natural substances can help keep your spine healthy by stopping harmful mineral buildup in soft tissues, which could lead to new treatments for back pain and spinal problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | February 1, 2024 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $599,407 |
| NIH project number | 5R01AR082460-02 |
| Project ID | NIH-11017795 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from chronic low back pain, spinal degeneration, or related autoimmune conditions.
✕Less likely to help
Patients with acute spinal injuries or those without any spinal health issues may not benefit from this research.
What this research studies
This research focuses on understanding the role of low molecular weight mineralization inhibitors in maintaining spine health. It examines how these inhibitors can prevent ectopic mineralization, which is the abnormal deposition of minerals in soft tissues, particularly in the intervertebral discs. By studying the mechanisms behind this process, the research aims to identify potential therapeutic targets for conditions like chronic back pain and spinal degeneration. Patients may benefit from insights that could lead to new treatments for spine-related issues.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent or treat chronic back pain and spinal degeneration.
How similar studies have gone: Other research has shown promise in understanding mineralization processes, but this specific focus on spinal health and low molecular weight inhibitors is relatively novel.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Van de Wetering, Koen — Thomas Jefferson University
- Study coordinator: Van de Wetering, Koen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.